J Rheum Dis.  2013 Aug;20(4):209-217. 10.4078/jrd.2013.20.4.209.

Skin and Rheumatic Disease

• Lee ES

• KMID: 2297534
• DOI: http://doi.org/10.4078/jrd.2013.20.4.209

Abstract

Many rheumatic diseases may involve any organ system of the body including the skin. Proper understanding of rheumatic skin disease is necessary for making a diagnosis. In addition, there are important relationships existing between the cutaneous and systemic manifestations of rheumatic diseases. In management of these diseases, the interdisciplinary approach could generate better results. Among rheumatic diseases, the cutaneous manifestations of three major rheumatic diseases such as lupus erythematosus (LE), dermatomyositis (DM)/polymyositis and scleroderma/systemic sclerosis (SSc) will all be reviewed.

Keyword

Rheumatic disease; Skin manifestsions; Lupus erythematosus; Dermatomyositis; Scleroderma

MeSH Terms

Dermatomyositis
Lupus Erythematosus, Systemic
Rheumatic Diseases
Polymyositis
Scleroderma, Systemic
Skin
Skin Diseases

Reference

References

1. Obermoser G. Lupus erythematosus and the skin: a jour-ney at times perplexing, usually complex, often challenging, and evermore exhilarating. Lupus. 2010; 19:1009–11.

2. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981; 4:471–5.

3. Sontheimer RD. The lexicon of cutaneous lupus erythematosus–a review and personal perspective on the no-menclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997; 6:84–95.

4. Costner MI, Sontheimer RD. Lupus Erythematosus. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Dallas NA, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed.New York: McGraw-Hill;2012.

5. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009; 145:249–53.

6. Kim YS, Lee CW. Clinical features of the skin lesions of patients with chronic cutaneous lupus erythematosus and examination of the factors that are relevant to its transformation to systemic lupus erythematosus. Korean J Dermatol. 2009; 47:268–77.

7. Kwon TE, Kwon OS, Chung JH, Cho KH, Youn JI. A clinicopathological study of chronic cutaneous lupus erythematosus. Korean J Dermatol. 1999; 37:459–67.

8. Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol. 2004; 22:121–4.

9. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010; 19:1050–70.

10. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009; 301:65–70.

11. Lee CW, Kim JS. Clinical features of subacute cutaneous lupus erythematosus among Koreans. Korean J Dermatol. 1997; 35:90–5.

12. Bae YI, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in Korea. Lupus. 2009; 18:1320–6.

13. Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007; 5:1124–37.

14. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev. 2005; 4:296–302.

15. Zecević RD, Vojvodić D, Ristić B, Pavlović MD, Stefanović D, Karadaglić D. Skin lesions–an indicator of disease activity in systemic lupus erythematosus? Lupus. 2001; 10:364–7.

16. Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Derma-tological, systemic and laboratory findings in 191 patients. Dermatology. 1995; 190:277–83.

17. Albrecht J, Berlin JA, Braverman IM, Callen JP, Connolly MK, Costner MI, et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus. 2004; 13:839–49.

18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25:1271–7.

19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40:1725.

20. Ahn JK. Clinical manifestations and diagnosis of systemic lupus erythematosus. Korean J Med. 2010; 78:409–15.

21. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64:2677–86.

22. Clarke JT, Werth VP. Rheumatic manifestations of skin disease. Curr Opin Rheumatol. 2010; 22:78–84.

23. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002; 20:387–408.

24. Sontheimer RD, Hansen CB, Costner MI. Dermatomyositis. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Dallas NA, editors. Fitzpatrick's dermatology in general medicine. 8th ed.New York: McGraw-Hill;2012.

25. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and thera-peutics. Best Pract Res Clin Rheumatol. 2004; 18:429–62.

26. Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007; 57:937–43.

27. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010; 146:26–30.

28. Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis. 2004; 63(Suppl 2):ii79–ii83.

29. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, Sáez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009; 27:1009–16.

30. Goodfield MJD, Jones SK, Veale DJ. The ‘Connective Tissue Disease’. Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. 8th ed.Oxford: Wiley-Blackwell;2010.

31. Fett N, Werth VP. Update on morphea: part I. Epidemio-logy, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011; 64:217–28.

32. Moinzadeh P, Denton CP, Krieg T, Black CM. Scleroderma. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Dallas NA, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed.New York: McGraw-Hill;2012.

33. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009; 145:545–50.

34. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol. 2004; 16:718–22.

35. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011; 65:925–41.

36. Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011; 64:231–42.